If you have been reading about 有关物质 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
The War of 1812 coincided with the War of the Sixth Coalition. Historians in the United States and Canada see it as a war in its own right, while Europeans often see it as a minor theatre of the Napoleonic Wars. The United States declared war on Britain due to a variety of reasons, including British support for Native Americans resisting US settler expansion, interference with American merchant shipping, the impressment of Royal Navy deserters from US merchantmen, and expansionist American desires to occupy Canada. France had interfered with American shipping as well, and the United States had considered declaring war on France. The war ended in a military stalemate under the Treaty of Ghent, which took effect in early 1815 when Napoleon was still in Elba and returned the pre-war boundaries.
Those coming from a minority background often receive lower quality care, they are less likely to get anti-AD medications compared to their White counterparts. Furthermore, when they are prescribed medication, they are less likely to adhere to the treatment due to various factors and barriers such as the quality of interaction with healthcare providers, distrust in doctors, worries about retaining personal autonomy, stigmas and different beliefs.
== History == The incidence of acute rheumatic fever and rheumatic heart disease is not declining. Recent figures quote the incidence of Acute Rheumatic Fever as 0.6–0.7/1,000 population in the United States and Japan compared with 15–21/1,000 population in Asia and Africa. The prevalence of Acute Rheumatic Fever and Sydenham's Chorea has declined progressively in developed countries over the last decades.
Sources: en.wikipedia.org
Commonly fluorophores (such as rhodamine or fluorescein) are linked to the ring linked to the sugar (in para) via a flexible arm, presumably extruding from the major groove of the helix. Due to low processivity of the nucleotides linked to bulky adducts such as fluorophores by Taq polymerases, the sequence is typically copied using a nucleotide with an arm and later coupled with a reactive fluorophore (indirect labelling):
=== Legal status === United States: During clinical trials a small number of users (~4%) reported euphoria after use, which led to its control in the US. The Drug Enforcement Administration (DEA) classified pregabalin as a depressant and placed pregabalin, including its salts, and all products containing pregabalin into Schedule V of the Controlled Substances Act. Norway: Pregabalin is in prescription Schedule B, alongside benzodiazepines. United Kingdom: On January 14, 2016, the Advisory Council on the Misuse of Drugs (ACMD) recommended that pregabalin, along with gabapentin, be controlled under the Misuse of Drugs Act 1971. In October 2018, it was announced that pregabalin would be reclassified as a Class C controlled substance, effective April 2019. As a Class C drug, pregabalin now requires a prescription in the UK, and the prescription must clearly specify the dose. Australia: Pregabalin has been classified as Schedule 4 (prescription only) since its registration in Australia in 2005. Despite this classification, concerns about misuse and deaths led the Therapeutic Goods Administration (TGA) to add boxed warnings regarding abuse and dependence to pregabalin's prescribing information in 2021. Data from the National Coronial Information System showed pregabalin-related deaths rose from 16 in 2013 to 121 in 2016, and a 2019 study in the Medical Journal of Australia found over a tenfold increase in pregabalin-related ambulance attendances in Victoria between 2012 and 2017. Pregabalin is subject to real-time prescription monitoring in all states and territories.
==== Editing ==== In some instances, an mRNA molecule is edited, which changes the nucleotide composition of the transcript. A prominent example in humans involves the apolipoprotein B mRNA. In certain tissues, RNA editing of this transcript creates a premature stop codon, which results in the production of a shorter protein variant. Another well studied mechanism is A-to-I (adenosine-to-inosine) editing. This reaction is catalyzed by ADAR enzymes (adenosine deaminase acting on RNA) and typically occurs within double-stranded RNA regions. A-to-I editing may occur in both coding sequences and untranslated regions. Through these modifications, the process can affect protein recoding, RNA structure, and gene regulation.
==== Stress and addiction ==== Stress contributes to both the development and the persistence of addiction, affecting neurophysiological pathways, decision-making and relapse risk. Acute and chronic stress activate the hypothalamic–pituitary–adrenal axis, raising levels of cortisol and corticotropin-releasing hormone; these changes alter reward processing and increase the motivational pull of substances, particularly those that temporarily relieve negative mood. In animal studies, repeated stress exposure increases dopamine release in the nucleus accumbens and sensitizes the mesolimbic reward system, making drugs more reinforcing. Chronic stress also disturbs glutamatergic signaling in the prefrontal cortex, impairing inhibitory control and self-regulation, which increases susceptibility to compulsive drug seeking and reduces the ability to disregard drug-associated cues. Stress is among the more reliable predictors of relapse. In human neuroimaging studies, stress-induced activation of the amygdala together with reduced prefrontal regulation is associated with self-reported craving and with subsequent return to use. People with a history of trauma, or of chronic social stress such as discrimination, poverty or housing insecurity, are at increased risk of substance use disorders. Because stress interacts with reward circuitry and decision-making systems, many treatment approaches incorporate stress-reduction strategies, including cognitive behavioral therapy, mindfulness-based interventions and medications acting on stress-related neurochemistry.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.